Business Context and Reporting Period
This Form 6-K filing by GSK plc (the "Company") reports a transaction in its own shares. The filing date is June 12, 2025, covering a share repurchase executed on June 11, 2025. The Company is a Foreign Private Issuer filing under Rule 13a-16 of the Securities Exchange Act of 1934.
Key Financial Metrics and Transaction Details
The filing details a specific share buyback transaction rather than providing comprehensive financial statements (revenue, profit, cash flow, or debt levels are not included in this document).
- Shares Purchased: 325,916 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 1,508.00 GBp; highest price paid was 1,527.50 GBp.
- Average Price: Volume-weighted average price paid was 1,518.52 GBp.
- Trading Venue: London Stock Exchange (XLON).
- Broker: Merrill Lynch International.
- Treasury Shares Held: Following this purchase, the Company holds 220,271,170 ordinary shares in treasury.
- Shares in Issue: 4,095,011,741 ordinary shares (excluding Treasury shares).
- Voting Rights: Treasury shares represent 5.38% of total voting rights.
Material Changes and Program Status
This purchase was effected pursuant to a non-discretionary agreement entered into with the broker on June 4, 2025. Since the commencement of this specific agreement on June 4, 2025, the Company has purchased a total of 2,136,787 ordinary shares. The purchased shares are held as Treasury shares and do not carry voting rights.
Guidance, Outlook, and Risks
The filing contains a standard cautionary statement regarding forward-looking statements. GSK notes that projections are subject to risks and uncertainties that may cause actual results to differ materially. Specific risk factors are referenced in the Company's Annual Report on Form 20-F for 2024 and its Q1 Results for 2025. No new guidance or management commentary regarding operational outlook is provided in this specific filing.
Investor Verification Checklist
- Verify the total number of shares purchased under the non-discretionary agreement since June 4, 2025 (stated as 2,136,787).
- Confirm the updated percentage of voting rights held in treasury (stated as 5.38%).
- Review the "Risk Factors" section in the 2024 Form 20-F and Q1 2025 results for context on forward-looking statements.
- Check the total number of shares in issue (4,095,011,741) for denominator calculations regarding shareholder notification thresholds.